Brevan Howard Capital Management LP
Position in GILD — Gilead Sciences, Inc.
CIK 1512857
ST. HELIER, Y9
Position in GILD
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$15,581,385
+$10,114,319 QoQ
Shares Held
123,329
+214.4% QoQ
Ownership
0.010%
of shares outstanding
% of Portfolio
0.28%
of 13F equity value
Holder Rank
#361
of 2,266 holders
Holding Since
Jun 2024
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in GILD Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Brevan Howard Capital Management LP holds $180,596,811 across 9 Drug Manufacturers - General names. GILD ranks #4 (8.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
77,094 | $92,468,863 | |
| 2 | ABBV |
AbbVie Inc.
|
115,264 | $29,005,032 | |
| 3 | JNJ |
Johnson & Johnson
|
62,412 | $15,850,774 | |
| 4 | GILD |
Gilead Sciences, Inc.
This page
|
123,329 | $15,581,385 | |
| 5 | BMY |
Bristol Myers Squibb Co
|
163,962 | $9,447,490 | |
| 6 | AMGN |
Amgen Inc
|
18,788 | $6,803,510 | |
| 7 | MRK |
Merck & Co., Inc.
|
50,031 | $6,428,983 | |
| 8 | AZN |
Astrazeneca PLC
|
20,152 | $3,821,222 |
All Filings in GILD
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $15,581,385 | 123,329 | Shares | Defined | 2026-08-14 | |
| 2026-03-31 | $5,467,066 | 39,227 | Shares | Defined | 2026-05-15 | |
| 2025-12-31 | $14,070,790 | 114,639 | Shares | Defined | 2026-02-17 | |
| 2025-09-30 | $2,237,427 | 20,157 | Shares | Defined | 2025-11-14 | |
| 2025-06-30 | $3,274,767 | 29,537 | Shares | Defined | 2025-08-14 | |
| 2025-03-31 | $4,501,608 | 40,175 | Shares | Defined | 2025-05-15 | |
| 2024-06-30 | $647,335 | 9,435 | Shares | Defined | 2024-08-14 | |
| No filing history on record for this holder in this stock. | ||||||